ChiCTR2200058633Not yet recruiting
Untitled Trial
A prospective, single-arm, single-center clinical study of Sintilizumab and bevacizumab combined with standard chemotherapy in the second-line treatment of metastatic colorectal cancer
The First Affiliated Hospital of Guangxi Medical UniversityPhase 2Chinese Clinical Trial Registry
Study focus
- Disease/Condition
- Colorectal cancer
Sponsor & location
- Primary sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Funder
- Self-financing
- Location
- China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- N/A
- End date
- Aug 31, 2024
ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200058633
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200058633 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Guangxi Medical University and is currently Not yet recruiting. The study focuses on Colorectal cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.